Stem cells harvested from different sources ameliorate liver fibrosis: comparative study.
Ali IS., Abdel-Wahab ND., Nabil A.
Animal Study, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cell Res Ther (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41168842
- PMCID
- PMC12577378
- DOI
- 10.1186/s13287-025-04707-6
Abstract (original English)
Hepatic fibrosis is a serious illness that can lead to death. Until recently, there has been no effective medication to protect the liver and heal fibrosis. When thioacetamide (TAA)-induced hepatotoxicity occurred, we aimed to determine the hepatoprotective effectiveness of adipose, bone marrow, and liver-derived mesenchymal stem cells. Fifty male albino Wistar rats were used throughout the study and divided into 5 groups. Each group had 10 rats divided into 2 cages, 5 rats per cage. Forty male albino Wistar rats were injected intraperitoneally with 100 mg/kg of thioacetamide 2 times a week for 9 weeks. After 5 weeks of induction of liver fibrosis, forty rats were divided into four groups. One group was considered the TAA group and didn't receive any treatment, and the other three groups were inoculated with a single dose of 3 × 10 6 BM-MSCs, AD-MSCs, and L-MSCs, respectively. We assessed the liver function tests as ALT, AST, and total bilirubin, which showed a significant decrease in groups inoculated with stem cells. But although the most significant decrease appeared in the L-MSCs inoculated group. Additionally, there was a notable rise in albumin levels in the L-MSC-inoculated group. In groups injected with stem cells, namely L-MSCs, the evaluation of antioxidant and oxidative stress levels revealed a substantial increase in GSH concentration, SOD activity, and CAT activity
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.